Clinical trial
Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's…
NCT00141700 · University of Michigan Rogel Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00141700 |
|---|---|
| Title | Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma |
| Official title | Rituximab Plus High-Dose Chemotherapy With Autologous Stem Cell Support for Poor-Prognosis Non-Hodgkin's Lymphoma |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin's |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 30 |
| Start date | Mar 1, 2003 |
| Primary completion | Mar 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Sep 1, 2005 |
| Last update posted | Jan 10, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: